Collectively, the combination of IRAK1/4 inhibitor and imatinib is an attractive therapeutic strategy for the elimination of imatinib-insensitive CML LSCs. The gene discussed is IRAK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.